信立泰(002294.SZ)：创新小分子药物SAL0140片获得临床试验批准

Core Viewpoint - The company, Xinlitai (002294.SZ), has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [1] Group 1: Drug Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company, targeting conditions such as uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD) [1] - The drug is expected to mitigate end-organ damage through the inhibition of aldosterone synthesis, potentially improving the progression of chronic kidney disease [1] Group 2: Mechanism of Action - Aldosterone is a crucial mineralocorticoid hormone that maintains fluid and electrolyte balance by activating mineralocorticoid receptors (MR), and it is directly involved in various cardiovascular and renal diseases [1] - Aldosterone synthase inhibitors may offer therapeutic benefits by reducing both genomic and non-genomic effects associated with end-organ damage [1]